BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, Jekarl DW, Lee S. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64:516-522. [PMID: 24035756 DOI: 10.1016/j.cyto.2013.07.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Qi F, Wang L, Huang P, Zhao Z, Yang B, Xia J. Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncol Lett 2020;19:1175-86. [PMID: 31966047 DOI: 10.3892/ol.2019.11209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Han NI, Yoon SK. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019;9:3260. [PMID: 30824840 DOI: 10.1038/s41598-019-40078-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
3 Li B, Su H, Cao J, Zhang L. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma. Cytokine 2017;89:91-7. [PMID: 27663978 DOI: 10.1016/j.cyto.2016.08.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
4 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu Y, Fan W, Xue M, Zhong B, Zhang S, Wang Y, Yao W, Zhao Y, Li J. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Oncologist 2019;24:e1489-95. [PMID: 31249138 DOI: 10.1634/theoncologist.2018-0669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lin W, Wang H, Zhong M, Yu S, Zhao S, Liang S, Du J, Cheng B, Gu W, Ling C. Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:6529376. [PMID: 33505496 DOI: 10.1155/2021/6529376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fernandez-ros N, Iñarrairaegui M, Paramo JA, Berasain C, Avila MA, Chopitea A, Varo N, Sarobe P, Bilbao JI, Dominguez I, D'avola D, Herrero JI, Quiroga J, Sangro B. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int 2015;35:1590-6. [DOI: 10.1111/liv.12592] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
8 Afiat TP, Johns C, Smith J, Kis B, Druta M. Adrenal crisis and death following transarterial chemoembolization of sarcoma liver metastases. Clin Imaging 2021;69:79-81. [PMID: 32693227 DOI: 10.1016/j.clinimag.2020.06.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
10 Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Radiology 2019;292:25-34. [PMID: 31012818 DOI: 10.1148/radiol.2019182326] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
11 Takaki H, Imai N, Contessa TT, Srimathveeravalli G, Covey AM, Getrajdman GI, Brown KT, Solomon SB, Erinjeri JP. Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization. J Vasc Interv Radiol 2016;27:1561-8. [PMID: 27084711 DOI: 10.1016/j.jvir.2016.01.150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
12 Abikhair M, Mitsui H, Yanofsky V, Roudiani N, Ovits C, Bryan T, Oberyszyn TM, Tober KL, Gonzalez J, Krueger JG, Felsen D, Carucci JA. Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. JCI Insight 2016;1:e86434. [PMID: 27699266 DOI: 10.1172/jci.insight.86434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
13 Santana AL, Felsen D, Carucci JA. Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma. Dermatol Clin. 2017;35:73-84. [PMID: 27890239 DOI: 10.1016/j.det.2016.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol 2019;70:999-1007. [PMID: 30738077 DOI: 10.1016/j.jhep.2019.01.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 25.0] [Reference Citation Analysis]
15 Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 2014;25:257-271. [PMID: 24856143 DOI: 10.1016/j.cytogfr.2014.04.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 78] [Article Influence: 13.6] [Reference Citation Analysis]
16 Wu ZJ, Xie YF, Chang X, Zhang L, Wu HY, Liu JB, Zhang JX, Sun P. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization. Med Sci Monit 2021;27:e929884. [PMID: 33967266 DOI: 10.12659/MSM.929884] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31952209 DOI: 10.3390/cancers12010212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
18 Wischhusen JC, Chowdhury SM, Lee T, Wang H, Bachawal S, Devulapally R, Afjei R, Sukumar UK, Paulmurugan R. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. J Control Release 2020;321:272-84. [PMID: 32004588 DOI: 10.1016/j.jconrel.2020.01.051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
19 Qu K, Yan Z, Wu Y, Chen Y, Qu P, Xu X, Yuan P, Huang X, Xing J, Zhang H, Liu C, Zhang J. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma: Chemoembolization aggravated fibrosis. J Gastroenterol Hepatol 2015;30:925-32. [DOI: 10.1111/jgh.12873] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
20 Jekarl DW, Kim JY, Lee S, Kim M, Kim Y, Han K, Woo SH, Lee WJ. Diagnosis and evaluation of severity of sepsis via the use of biomarkers and profiles of 13 cytokines: a multiplex analysis. Clinical Chemistry and Laboratory Medicine (CCLM) 2015;53. [DOI: 10.1515/cclm-2014-0607] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
21 Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2014;40:1270-81. [DOI: 10.1111/apt.12992] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
22 Avritscher R, Jo N, Polak U, Cortes AC, Nishiofuku H, Odisio BC, Takaki H, Tam AL, Melancon MP, Yevich S, Qayyum A, Kaseb A, Kichikawa K, Gupta S, Goldberg SN, Chang SH. Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:311-21. [PMID: 31591689 DOI: 10.1007/s00270-019-02343-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Advanced Drug Delivery Reviews 2014;79-80:222-37. [DOI: 10.1016/j.addr.2014.09.009] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 15.7] [Reference Citation Analysis]
24 Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol 2016;13:611-26. [PMID: 27118493 DOI: 10.1038/nrclinonc.2016.57] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 14.2] [Reference Citation Analysis]
25 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zhao J, Li Q, Muktiali M, Ren B, Hu Y, Li D, Li Z, Li D, Xie Y, Tao M, Liang R. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. BMC Cancer 2020;20:812. [PMID: 32847533 DOI: 10.1186/s12885-020-07326-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020;7:11-17. [PMID: 32104669 DOI: 10.2147/jhc.s187121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]